Envision Healthcare (EVHC) Expected to Announce Quarterly Sales of $2.02 Billion

Analysts expect Envision Healthcare (NYSE:EVHC) to post sales of $2.02 billion for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Envision Healthcare’s earnings, with the lowest sales estimate coming in at $1.97 billion and the highest estimate coming in at $2.08 billion. Envision Healthcare posted sales of $1.88 billion during the same quarter last year, which suggests a positive year over year growth rate of 7.4%. The business is expected to report its next earnings report after the market closes on Monday, May 7th.

According to Zacks, analysts expect that Envision Healthcare will report full year sales of $8.41 billion for the current year, with estimates ranging from $8.35 billion to $8.46 billion. For the next fiscal year, analysts forecast that the business will report sales of $8.98 billion per share, with estimates ranging from $8.75 billion to $9.29 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Envision Healthcare.

How to Become a New Pot Stock Millionaire

Envision Healthcare (NYSE:EVHC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.14. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Envision Healthcare had a negative net margin of 2.52% and a positive return on equity of 4.62%. The company’s quarterly revenue was up 68.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 EPS.



EVHC has been the subject of several research reports. SunTrust Banks raised their price objective on shares of Envision Healthcare to $45.00 and gave the company a “buy” rating in a research report on Thursday, March 1st. Jefferies Group set a $46.00 price objective on shares of Envision Healthcare and gave the company a “buy” rating in a research report on Wednesday, February 7th. Canaccord Genuity restated a “buy” rating and issued a $46.00 price objective (up previously from $32.00) on shares of Envision Healthcare in a research report on Wednesday, February 28th. Robert W. Baird set a $45.00 price objective on shares of Envision Healthcare and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Royal Bank of Canada restated a “buy” rating and issued a $48.00 price objective on shares of Envision Healthcare in a research report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $42.57.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in Envision Healthcare by 21.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,986,612 shares of the company’s stock worth $89,289,000 after acquiring an additional 352,654 shares during the last quarter. Stifel Financial Corp boosted its stake in Envision Healthcare by 29.6% during the 3rd quarter. Stifel Financial Corp now owns 11,741 shares of the company’s stock worth $528,000 after acquiring an additional 2,681 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in Envision Healthcare by 26.5% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 12,627 shares of the company’s stock worth $568,000 after acquiring an additional 2,649 shares during the last quarter. California Public Employees Retirement System boosted its stake in Envision Healthcare by 2.1% during the 3rd quarter. California Public Employees Retirement System now owns 251,887 shares of the company’s stock worth $11,322,000 after acquiring an additional 5,247 shares during the last quarter. Finally, Hexavest Inc. boosted its stake in Envision Healthcare by 1.1% during the 4th quarter. Hexavest Inc. now owns 655,516 shares of the company’s stock worth $22,655,000 after acquiring an additional 7,270 shares during the last quarter.

EVHC traded up $0.52 during midday trading on Friday, hitting $37.55. The company had a trading volume of 627,019 shares, compared to its average volume of 2,512,115. The company has a current ratio of 3.40, a quick ratio of 3.38 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $4,511.71, a PE ratio of 14.93, a PEG ratio of 0.86 and a beta of 0.42. Envision Healthcare has a twelve month low of $23.77 and a twelve month high of $64.00.

TRADEMARK VIOLATION NOTICE: “Envision Healthcare (EVHC) Expected to Announce Quarterly Sales of $2.02 Billion” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/04/25/envision-healthcare-evhc-expected-to-announce-quarterly-sales-of-2-02-billion.html.

Envision Healthcare Company Profile

Envision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company operates through two segments, Physician Services and Ambulatory Services. As of December 31, 2017, its physician-led services encompassed providers at approximately 1,800 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services.

Get a free copy of the Zacks research report on Envision Healthcare (EVHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply